

**Acknowledgement and Consent for Disclosure of Potential Conflict(s) of Interest  
and Waiver(s) under 18 U.S.C. §208(b)(3)**

**Elizabeth B. Andrews, M.P.H., Ph.D.**

**Committee: Drug Safety and Risk Management Advisory Committee**

**Meeting Date: February 9, 2006**

**I acknowledge that contingent upon public disclosure of the financial interests listed below related to the agenda item: Approaches that could be used to study whether Attention Deficit Hyperactivity Disorder (ADHD) products increase the risk of adverse cardiovascular outcomes, I will be permitted to give a presentation on, "*Challenges of Cardiovascular Drug Safety Epidemiology in the Post-Market Drug Arena*" and answer questions related to my presentation, and that I am eligible to receive a limited waiver under 18 U.S.C. §208(b)(3).**

<b><u>Type of Interest</u></b>	<b><u>Nature</u></b>	<b><u>Magnitude</u></b>
<b>Consulting on Unrelated Matters.</b>	<b>Three Affected Firms</b>	<b>Less than \$10,001 per year from each firm. Paid direct to employer.</b>

**I hereby request that FDA make this information publicly available on my behalf. I understand that without public disclosure of the interests, the waiver is not valid.**

**\_\_\_\_\_  
/S/  
Signature of SGE**

**\_\_\_\_\_  
1/30/2006  
Date**